Chiral Pharmacokinetics and Metabolite Profile of Prolonged-release Ketamine Tablets in Healthy Human Subjects.

Background: The anesthetic ketamine after intravenous dosing is nearly completely metabolized to R- and S-stereoisomers of the active norketamine (analgesic, psychoactive) and 2,6-hydroxynorketamine (potential analgesic, antidepressant) as well as the inactive dehydronorketamine. Oral administration...

Descripción completa

Detalles Bibliográficos
Publicado en:Anesthesiology Vol. 135; no. 2; pp. 326 - 340
Autores principales: Hasan, Mahmoud, Modess, Christiane, Roustom, Tarek, Dokter, Anne, Grube, Markus, Link, Andreas, Rey, Hélène, Adler, Stefanie, Meissner, Konrad, Siegmund, Werner
Formato: research tables/charts Journal Article
Publicado: Lippincott Williams & Wilkins Aug2021
Acceso en línea:Ver este registro en EBSCOhost
fields @attributes:
  recordID: 1
pdfLink:
plink: https://search.ebscohost.com/login.aspx?direct=true&db=ccm&AN=151616953&site=ehost-live
header:
  @attributes:
    shortDbName: ccm
    uiTerm: 151616953
    longDbName: CINAHL Complete
    uiTag: AN
  controlInfo:
    bkinfo:
    dissinfo:
    jinfo:
      jid:
        00033022
        1V8
      jtl: Anesthesiology
      issn: 00033022
      maglogo: N
    pubinfo:
      dt: Aug2021
      vid: 135
      iid: 2
      pid: 433
      pub: Lippincott Williams & Wilkins
      place: Baltimore, Maryland
    artinfo:
      ui:
        151616953
        151616953
        NLM34019627
        151616953
        10.1097/ALN.0000000000003829
        NLM34019627
        151616953
      ppf: 326
      ppct: 14
      formats:
      tig:
        atl: Chiral Pharmacokinetics and Metabolite Profile of Prolonged-release Ketamine Tablets in Healthy Human Subjects.
      aug:
        au:
          Hasan, Mahmoud
          Modess, Christiane
          Roustom, Tarek
          Dokter, Anne
          Grube, Markus
          Link, Andreas
          Rey, Hélène
          Adler, Stefanie
          Meissner, Konrad
          Siegmund, Werner
        affil: Department of Clinical Pharmacology, University Medicine Greifswald, Greifswald, Germany.
      sug:
        subj:
          Analgesics Pharmacokinetics
          Ketamine Metabolism
          Ketamine Pharmacokinetics
          Analgesics Metabolism
          Female
          Ketamine Administration and Dosage
          Analgesics Administration and Dosage
          Research Subjects
          Delayed-Action Preparations
          Adult
          Male
          Human
          Young Adult
          Administration, Oral
          Reference Values
          Comparative Studies
          Multicenter Studies
          Evaluation Research
          Validation Studies
          Adult: 19-44 years
          Female
          Male
      ab: Background: The anesthetic ketamine after intravenous dosing is nearly completely metabolized to R- and S-stereoisomers of the active norketamine (analgesic, psychoactive) and 2,6-hydroxynorketamine (potential analgesic, antidepressant) as well as the inactive dehydronorketamine. Oral administration favors the formation of 2,6-hydroxynorketamines via extensive presystemic metabolism. The authors hypothesized that plasma exposure to 2,6-hydroxynorketamines relative to the psychoactive ketamine is greater after prolonged-release ketamine tablets than it is after intravenous ketamine.Methods: Pharmacokinetics of ketamine after intravenous infusion (5.0 mg) and single-dose administrations of 10, 20, 40, and 80 mg prolonged-released tablets were evaluated in 15 healthy white human subjects by means of a controlled, ascending-dose study. The stereoisomers of ketamine and metabolites were quantified in serum and urine by validated tandem mass-spectrometric assays and evaluated by noncompartmental pharmacokinetic analysis.Results: After 40 mg prolonged-release tablets, the mean ± SD area under the concentrations-time curve ratios for 2,6-hydroxynorketamine/ketamine were 18 ± 11 (S-stereoisomers) and 30 ± 16 (R-stereoisomers) compared to 1.7 ± 0.8 and 3.1 ± 1.4 and after intravenous infusion (both P < 0.001). After 10 and 20 mg tablets, the R-ratios were even greater. The distribution volumes at steady state of S- and R-ketamine were 6.6 ± 2.2 and 5.6 ± 2.1 l/kg, terminal half-lives 5.2 ± 3.4 and 6.1 ± 3.1 h, and metabolic clearances 1,620 ± 380 and 1,530 ± 380 ml/min, respectively. Bioavailability of the 40 mg tablets was 15 ± 8 (S-isomer) and 19 ± 10% (R-isomer) and terminal half-life 11 ± 4 and 10 ± 4 h. About 7% of the dose was renally excreted as S-stereoisomers and 17% as R-stereoisomers.Conclusions: Prolonged-release ketamine tablets generate a high systemic exposure to 2,6-hydroxynorketamines and might therefore be an efficient and safer pharmaceutical dosage form for treatment of patients with chronic neuropathic pain compared to intravenous infusion.Editor’s Perspective:
      pubtype: Academic Journal
      doctype:
        research
        tables/charts
        Journal Article
      ougenre: Article
    language: English
    refInfo:
    holdings:
      @attributes:
        islocal: N